ArticleScientific reports2025
MiR-106b-5p promotes gastric cancer progression by directly targeting the tumor suppressor RBL2.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gastric cancer (GC) is the fifth most common malignancy and the fifth highest cause of cancer-related deaths on a global scale. This study reveals that miR-106b-5p promotes malignant phenotypes in GC by targeting retinoblastoma-like protein 2 (RBL2). Using miR-106b-5p mimic/inhibitor and RBL2 overexpression plasmids in AGS/HGC-27 cells, this study demonstrates that miR-106b-5p promotes proliferation (CCK-8/clone formation) and migration/invasion (Transwell assay) and suppresses apoptosis (flow cytometry), while RBL2 rescues these effects. Luciferase assays confirm that miR-106b-5p directly binds the 3’UTR of RBL2 and western blotting demonstrates the presence of RBL2 downregulation. Animal studies further validate the tumour-promoting role of miR-106b-5p via RBL2 suppression, which suggests its therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.